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Abstract 
Immunosuppressive treatment increases the risk of infection and malignancy in organ 
transplant recipients. We report on a 42-year-old male renal transplant recipient who lost 
his first graft after reduction of immunosuppressive treatment due to Kaposi sarcoma 
and who successfully underwent a second renal transplant 10 years later. The patient’s 
current treatment consists of low-dose prednisone, and the two antiproliferative 
immunosuppressants mycophenolate mofetil and rapamycin. 4.5 years after his second 
transplant, the serum creatinine is 1 mg/dl and the patient has no signs of recurrent 
disease. 
 
Introduction 
Renal transplant recipients have a higher risk for infection and malignancy due to 
immunosuppression than the general population. A specific type of skin cancer is Kaposi 
sarcoma (fig. 1) originating from the dermal blood vessels. Kaposi sarcoma is classified in 
4 types: 1 = classic Kaposi sarcoma, 2 = iatrogenic (immunosuppressive Kaposi sarcoma), 
3 = AIDS-associated (epidemic) Kaposi sarcoma and 4 = endemic Kaposi sarcoma.  
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It is well known that Kaposi sarcoma is associated with human herpes virus 8 (HHV-
8). In 0.5–5% of seropositive transplant recipients reactivated HHV-8 leads to Kaposi 
sarcoma [1, 2]. 
In Northern Europe the seroprevalence of HHV-8 is 0–8%, whereas in the 
Mediterranean area and in the Middle East the seroprevalence is 10–25%. Kaposi sarcoma 
after renal transplantation is mainly found in patients of the Mediterranean area and of 
Middle Eastern descent [3]. 
We report for the first time a case of a successful second renal transplantation using 
sirolimus in a patient with a history of Kaposi sarcoma. The study by Stallone et al. [3] 
showed a complete remission of Kaposi sarcoma after conversion from calcineurin 
inhibitor to sirolimus within 6 months. 
Case Report 
We report on a 42-year-old male patient who developed Kaposi sarcoma with visceral involvement 
38 months after living-related renal transplantation. The patient originates from Turkey and has been 
living in Germany since he was born. 
End-stage renal disease was due to chronic glomerulonephritis, and the patient was on hemodialysis 
for 6 months prior to transplantation. The initial immunosuppressive regimen comprised prednisone, 
azathioprine and cyclosporine. Upon diagnosis of Kaposi sarcoma immunosuppression was reduced. 
Thereafter the patient had an episode of acute rejection requiring steroid treatment. Subsequently, the 
patient lost his graft 30 months after diagnosis of Kaposi sarcoma due to chronic rejection. A 
transplantectomy was performed 2 months after return to dialysis. No signs of recurrent disease were 
present on physical examination and on CT scan 13 months after cessation of immunosuppression. 
The patient was wait-listed after a period of 10 years and received a second transplant 5 weeks 
thereafter. His immunosuppressive regimen includes sirolimus (2 mg/day), mycophenolate mofetil 
(1,000 mg/day) and prednisone (4 mg/day). After a follow-up of 4.5 years, the patient showed stable 
graft function with a serum creatinine of 1.2 mg/dl (fig. 2). Recurrence of Kaposi sarcoma is closely 
monitored by physical examination and CT scans. To date our patient has no signs of tumor recurrence. 
Discussion 
To our knowledge, this is the first report on a renal transplant recipient with a previous 
history of transplant-related Kaposi sarcoma undergoing de novo renal transplantation 
with favorable long-term graft function and tumor control. Stallone et al. [3] reported on 
15 renal transplant recipients with Kaposi sarcoma in whom cyclosporine was replaced by 
sirolimus to achieve tumor control. A complete remission within several months was 
documented for the entire patient cohort, with no impact on graft function and no acute 
episodes of rejection.  
The mTOR inhibitor sirolimus has a known anti-tumor effect [4]. Previously, 
sirolimus-based immunosuppression has been shown to protect renal transplant 
recipients from de novo malignancies [5].  
In renal transplant recipients diagnosed with transplant-associated Kaposi sarcoma, 
conversion to sirolimus-based immunosuppressive protocols may result in long-term 
tumor control [6]. However, the use of less potent immunosuppressives bears the risk of 
early graft loss due to acute or chronic rejection. An immunosuppressive protocol based 
on antiproliferative drugs, including sirolimus and MMF, has been shown to protect renal 
grafts from rejection and to provide reliable tumor control as compared to standard 
calcineurin-based immunosuppression [7].  
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Our present case and recent literature suggest that de novo renal transplantation in 
recipients with a history of transplant-associated malignancy is feasible using an 
immunosuppressive protocol based on sirolimus and MMF. 
 
 
 
 
 
Fig. 1. Kaposi sarcoma, skin lesion. 
 
 
 
Fig. 2. Creatinine follow-up. 
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